Tagged: HIV

  • PrEP use and risk perception: What’s the connection?

    Now that the U.S. Food and Drug Administration has approved the use of the antiretroviral drug combination of tenofovir disoproxil fumarate and emtricitabine (Truvada®) for HIV prevention, its success will depend on user adherence to the daily drug regimen.

    Several trials of Truvada as pre-exposure prophylaxis (PrEP) showed it is most effective when adherence is high. Two trials, VOICE and FEM-PrEP, were unable to determine whether Truvada worked, likely because most participants did not take the study pills daily as directed.

    One explanation for low adherence to PrEP is that study participants might have thought they were not at risk of HIV infection.

    A study from FHI 360’s Preventive Technologies Agreement (PTA) explored this possibility. Our analysis of data from a randomly assigned cohort of 150 participants who received Truvada in the FEM-PrEP trial yielded some intriguing results, presented in a late-breaker poster this week at the International AIDS Society conference (IAS 2013) in Kuala Lumpur, Malaysia.

    Continue reading

  • Patriotism, sacrifice and an HIV vaccine

    Over the past week, scientists and advocates around the world refocused their attention on the search for an HIV vaccine. Fittingly the observance stems from a long ago speech by President Bill Clinton. On May 18, 1997, Mr. Clinton delivered an inspiring commencement address at Morgan State University in Baltimore, Maryland. In the speech, the president challenged the scientific community and the graduating class from one of America’s foremost historically black universities to invest their talents in the discovery of an HIV vaccine. Mr. Clinton also called for a worldwide commitment to develop an “AIDS vaccine within the next decade.” Since that commencement, May 18 has been marked by scientists, advocates and governments as HIV Vaccine Awareness Day.

    In the years following Mr. Clinton’s bold challenge, there have been gains and setbacks in our quest to find an HIV vaccine.

    In 2009, the world applauded when the U.S. Army’s research program and the Thai Ministry of Health announced the first HIV vaccine trial to show efficacy. The trial results showed that the candidate vaccines in the RV144 study worked in 31 percent of the people who were vaccinated. Although this level of efficacy is not sufficient to bring a product to market, it is a promising sign that a vaccine is indeed possible.

    Continue reading

  • ROADS II: Transforming corridors of risk into pathways of prevention and hope

  • FHI 360’s Deputy Country Director for Nigeria, Dr. Robert Chiegil, spoke with Voice of America’s health correspondent Linord Moudou yesterday about reducing the impact of HIV and TB in Nigeria and other African countries. Watch the video below.

  • Getting to zero: National Youth HIV and AIDS Awareness Day

    More than half of the world’s population is under the age of 30 and has never lived in a time without AIDS. Despite the steady progress of our collective scientific and community efforts to end the HIV epidemic, the lives of young people continue to be especially vulnerable. To bring attention to this ongoing crisis and to commit ourselves to achieving an AIDS-free generation, today marks the first National Youth HIV and AIDS Awareness Day.

    According to the U.S. Centers for Disease Control and Prevention (CDC), 50,000 people in the United States are infected with HIV each year. Of those, one in four is between 13 and 24 years old. Further, CDC reports that nearly 60 percent of new infections in youth occur in African Americans, 20 percent in Latinos and about 20 percent in whites. In 2010, CDC estimates that 87 percent of the 12,000 annual infections in youth occurred among gay and bisexual young men. Nearly half of all new infections among American youth occur in African American males.

    In a CDC Vital Signs report released for World AIDS Day 2012, the agency noted that “about 60 percent of youth do not know they are infected and so don’t receive treatment, putting them at risk for sickness and early death. These youth can also unknowingly pass HIV to others.”

    Continue reading

  • Partner reduction to avoid HIV risk is the focus for a new publication

    Promoting Partner Reduction title page

    Having multiple sexual partners, particularly when relationships overlap in time, is a major driver of the HIV epidemic. Overlapping, or concurrent, relationships increase the number of people who are connected in a “sexual network,” and HIV spreads more quickly the larger the sexual network. Although young people report having multiple sexual partners, few HIV prevention programs for youth tackle this topic.

    FHI 360, on behalf of USAID’s Interagency Youth Working Group, recently helped address this gap with a new publication, Promoting Partner Reduction: Helping Young People Understand and Avoid HIV Risks from Multiple Partnerships. The late Dr. Doug Kirby of ETR Associates was a major contributor.

    Continue reading

  • Preventing mother-to-child transmission of HIV in Zambia: Replicating success

    In 2010, around 390,000 children under age 15 became infected with HIV, mainly through mother-to-child transmission. However, with effective interventions, mother-to-child transmission can be virtually eliminated to save the lives of thousands of children every year. One effective, evidence-based intervention is the preventing mother-to-child transmission of HIV (PMTCT) component of FHI 360’s Zambia Prevention, Care and Treatment Partnership (ZPCT). This USAID-funded program, which ran from 2004–2009 —and was renewed through 2014 as ZPCT II— serves as a model for other countries.

    The ZPCT I program increased the percentage of pregnant women in antenatal clinics who accepted HIV tests and received test results from 45 to 99 percent. Among women who tested positive for HIV, the program increased the percentage of women who received a full course of antiretroviral prophylaxis from 29 to 100 percent. Most importantly, observational data from ZPCT sites showed an HIV acquisition rate of 6.5 percent among children ages 0 to 6 weeks where the mother and infant received interventions, compared with 20 percent where no intervention was given to either mother or baby. The fact that this highly effective intervention costs merely US$113–126 per mother makes a compelling case for replicating it in other contexts.

    To support program designers who wish to replicate this program, FHI 360 produced Preventing Mother-to-Child Transmission of HIV: Implementation Starter Kit. This starter kit describes and provides access to all programmatic materials and tools (such as training materials and job aids) used by ZPCT and provides basic guidance on replicating effective programs. We hope that such an effective and low-cost intervention will be reproduced in other country contexts and that it will generate the same life-saving results.

  • World AIDS Day 2012: A Shared Vision of Getting to Zero

    FHI 360 has been partnering toward an AIDS-free generation since the beginning of the epidemic. As we approach World AIDS Day 2012, FHI 360 experts examine next steps needed to tackle HIV/AIDS for good. We’ll discuss new enhancements in the testing and treatment of women during pregnancy and in the prevention of mother-to-child transmission of HIV. We’ll also take a look at the HIV treatment cascade and how it can help people to take the initiative to learn their HIV status and close some of the gaps in treatment and service. Finally, we will share perspectives from the field with a program profile and success story.

    As we look to the future, from our work in Cambodia to Kenya to the U.S., FHI 360 will continue to partner toward a shared vision of “getting to zero.”


  • A version of this post originally appeared on Natural Medicine. Reposted with permission.

    A new study published in the on line journal Nature Medicine over the weekend brings exciting news in the race to find an AIDS vaccine. Researchers from the Centre for the AIDS Programme of Research in South Africa (CAPRISA) have found that a key change in the outer coating of the HIV virus allowed two HIV positive women to develop “broadly neutralizing antibodies,” which are antibodies that can be used to target and fight most strains of HIV.

    The first broadly neutralizing antibodies were discovered over three years ago, and since then dozens more have been identified. But until now, researchers haven’t been able to pinpoint how they develop, which is critical to developing a vaccine. The new findings establish a link between a change in the virus after infection and the formulation of the antibodies that fight it.

    According to Anthony Fauci, director of the National Institute of Allergy and Infectious Diseases, the study is “an important step in trying to understand just how these broadly neutralizing antibodies evolve.”

    Continue reading

  • Ending AIDS Among Latino Americans: ¡Sí se puede!

    The past three years have seen tremendous breakthroughs in HIV prevention research. Since 2009, we have seen the first vaccine to show effectiveness, a microbicide that was found to be modestly efficacious and two studies demonstrating that an HIV medication could be used as a pre-exposure prophylaxis or could reduce new infections by treating those with HIV earlier. These advances have led many to herald a new era in our 30-year campaign to end the epidemic.

    Continue reading